非透析依赖慢性肾脏病合并缺血性心脏病血运重建的获益与风险
本系统评价与荟萃分析纳入9项随机对照试验,评估非透析依赖慢性肾脏病合并缺血性心脏病患者行血运重建与药物治疗相比的获益与风险。结果显示血运重建可能降低全因死亡率(RR 0.80,95%CI 0.64-0.98)和心血管事件风险,不良肾脏事件不常见但证据不足。
要点
- 血运重建可能降低非透析依赖CKD合并缺血性心脏病患者的全因死亡率。
- 血运重建可能减少心肌梗死和心力衰竭发生率,但证据质量低。
- 不良肾脏事件不常见,但证据不足,需更多研究。
核心结论
- 在非透析依赖CKD合并缺血性心脏病患者中,血运重建可能降低全因死亡率和心血管事件风险。
研究设计与样本
- 系统评价与荟萃分析,纳入9项随机对照试验,检索PubMed、Embase和Cochrane Central Register of Controlled Trials至2023年12月12日。
主要发现
- 血运重建组全因死亡率风险比RR 0.80(95%CI 0.64-0.98,证据质量低)。
- 心肌梗死风险比RR 0.81(95%CI 0.64-1.04,证据质量低)。
- 心力衰竭风险比RR 0.80(95%CI 0.52-1.23,证据质量低)。
- 心血管死亡风险比HR 0.67(95%CI 0.37-1.20,证据质量极低)。
- 患者报告结局和不良肾脏事件证据不足。
临床怎么用
- 对于非透析依赖CKD合并缺血性心脏病患者,血运重建可作为降低全因死亡率和心血管事件的考虑选项。
- 需结合患者具体情况,充分沟通肾脏和患者报告结局的不确定性,共同决策。
局限性
- 患者人群异质性大,试验数量有限。
- 患者报告结局和不良肾脏事件证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In people with non–dialysis-dependent CKD, revascularization may lower all-cause mortality and risk of cardiovascular events. Adverse kidney events, which are often cited as a reason to avoid revascularization, were uncommon. Additional research on the effect of revascularization on patient-reported outcomes in people with non–dialysis-dependent CKD is needed. BACKGROUND: Cardiovascular disease is the leading cause of death in people with CKD. Coronary revascularization can improve cardiac function and prognosis in people with ischemic heart disease; however, in people with CKD, there is concern that potential harms could outweigh benefits of revascularization. Evidence on the balance of these risks and benefits, specifically in people with non–dialysis-dependent CKD, is lacking. METHODS: We conducted a systematic review of randomized controlled trials to assess the risks and benefits of revascularization, compared with medical management, among adults or children with ischemic heart disease and CKD not requiring KRT (dialysis or transplantation). We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials through December 12, 2023. Two people independently screened titles and abstracts followed by full-text review, serially extracted data using standardized forms, independently assessed risk of bias, and graded the certainty of evidence (COE). RESULTS: Evaluating data from nine randomized controlled trials, we found that people with CKD and ischemic heart disease treated with revascularization may experience lower all-cause mortality compared with people receiving medical management (risk ratio [RR], 0.80; 95% confidence interval [CI], 0.64 to 0.98; COE, low). Revascularization may reduce incidence of myocardial infarction (RR, 0.81; 95% CI, 0.64 to 1.04; COE, low) and heart failure (RR, 0.80; 95% CI, 0.52 to 1.23; COE, low). The effect on cardiovascular mortality is uncertain (hazard ratio, 0.67; 95% CI, 0.37 to 1.20; COE, very low). Evidence was insufficient for patient-reported outcomes and adverse kidney events. Data were limited by heterogeneity of patient populations and the limited number of trials. CONCLUSIONS: In people with non–dialysis-dependent CKD, revascularization may be associated with lower all-cause mortality compared with medical management and may also lower the risk of cardiovascular events. Additional data surrounding kidney and patient-reported outcomes are needed to comprehensively engage in shared decision making and determine optimal treatment strategies for people with CKD and ischemic heart disease. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: CRD42022349820 (PROSPERO).
引用
- Patel DM, Wilson LM, Wilson RF, et al. Benefits and Harms of Coronary Revascularization in Non-Dialysis-Dependent Chronic Kidney Disease and Ischemic Heart Disease: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2024. PMID: 39506892. doi:10.2215/CJN.0000000000000549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。